The Efficacy and Safety of Nab‐Paclitaxel Plus Anlotinib in Small‐Cell Lung Cancer for Second‐Line Therapy
ABSTRACT Background Extensive Small‐cell lung cancer (ES‐SCLC) has a poor prognosis following the failure of first‐line therapy based immune checkpoint inhibitors. This study aimed to evaluate the efficacy and safety of nab‐paclitaxel combined with anlotinib as second‐line treatment for relapsed SCL...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wiley
2026-05-01
|
| coleção: | Thoracic Cancer |
| Acesso em linha: | https://doi.org/10.1111/1759-7714.70290 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|